July 23, 2013
/PRNewswire/ -- Exosome Diagnostics and QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced a partnership to develop and commercialize high-performance, co-branded kit products for the capture and processing of RNA and DNA from biofluid exosomes and other microvesicles. The partnership will accelerate global availability of Exosome Diagnostics' platform technology products enabling researchers and drug developers to obtain repeated, real-time genetic "snapshots" of disease from patients' blood, urine or cerebrospinal fluid without the need for tissue biopsy. The companies are targeting initial product launches in the first half of 2014. Financial terms were not disclosed.
"QIAGEN is the industry leader in clinical sample preparation and our partnership brings global development, manufacturing, distribution and marketing expertise to the Exosome technology platform," said
, chief executive officer of Exosome Diagnostics. "Data emerging from research use of Exosome/QIAGEN kits will provide additional validation of the exosome technology platform and lead to clinical
diagnostic applications in multiple settings including oncology and neurodegenerative disease."
, M.D., director of the Termeer Center for Targeted Therapy at Massachusetts General Hospital and associate professor,
Harvard Medical School
said, "Monitoring patients response in exosomes isolated from blood, as opposed to tumor biopsies, offers the possibility of optimizing the use of targeted therapies in cancer patients. The ability to rapidly diagnose mutation status without need of a biopsy, monitor response to therapy without radiology, and detect emergence of resistance at the earliest possible point, will allow us to initiate therapy more rapidly and switch treatments before a patient's cancer worsens in a way that compromises their quality of life. Our clinical research focus is to define both response and resistance biomarkers to novel therapies, all of which can be enabled by exosomes."
, M.D., director of Urologic Oncology,
said, "The ability to achieve a stable, high quality RNA preparation directly from a simple urine sample has significant implications for interrogating the prostate, the bladder and the kidney on a molecular level, all non-invasively. Through over 1,500 patient samples measured in clinical studies, we have shown that Exosome Diagnostics technology enables reproducible, sensitive measure of cancer specific molecular biomarkers directly from a simple, untreated urine sample."
Subject to successful completion of the solutions' performances, QIAGEN's exclusive agreement with Exosome Diagnostics will cover co-development, manufacturing and commercialization of a full product line for the life science and translational medicine markets. The product portfolio is also expected to create the basis development and commercialization of clinical
diagnostic products for a range of non-invasive personalized medicine solutions.
Exosomes and other extracellular vesicles can be isolated from biofluids such as blood, urine and cerebrospinal fluid and from which high quality nucleic acids, such as mRNA, miRNA and DNA, can be extracted and purified for analysis. Exosomes are shed by all cells under both normal and pathological conditions. They are a key part of the body's complex communication system that transfers genetic instructions from cell to cell through all biofluids. Exosomes carry nucleic acids and proteins from their host cell, which are widely considered to be essential for biomarker discovery for personalized medicine diagnostics. Tumor cells, for instance, release exosomes which contain tumor-specific RNA that can be more easily isolated from biofluids than from tissue biopsies.